CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021
CIN: U85110UP2003PLC193493
TELNO.: -8069366666 **Email:** secretarial@chandan.co.in
www.chandandiagnostic.com

Date: October 10, 2025

To,
Listing Compliance Department
National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra East, Mumbai – 400051.

Dear Sir/Madam,

Subject: Outcome of Board meeting held today i.e. on October 10, 2025. Reference: Chandan Healthcare Limited (Symbol: CHANDAN)

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held on today, i.e. on October 10, 2025, at the Registered Office of the Company which was commenced at 10:00 A.M. and concluded at 10:30 A.M., have, apart from other businesses;

1. Approved the increase in the Authorized Share Capital of the Company from existing Rupees 25,00,00,000.00 (Rupees Twenty Five Crore only) divided into 2,50,00,000 Equity Shares of Rupees 10.00 each to Rupees 30,00,00,000.00 (Rupees Thirty Crores Only) divided into 3,00,00,000 Equity Shares of Rupees 10.00 each and thereby consequent alteration to the Memorandum of Association of the Company, subject to approval of shareholders and Securities and Exchange Board of India;

   The detailed disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular is enclosed as '**ANNEXURE A**'.

2. Approved issue and allotment of up to 44,50,000 Fully Convertible Equity Warrants ("Equity Warrant(s)") each convertible into or exchangeable for, 1 (one) fully paid up equity share of the Company of face value of Rupees 10.00 each, on a preferential basis ("Preferential Issue"), at an issue price as may be determined in accordance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("ICDR Regulations"), as amended and other applicable laws, subject to the approval of regulatory / statutory authorities and the shareholders of the Company at the Extraordinary General Meeting.

   The requisite details as required under Regulation 30 of SEBI Listing Regulations, read with Schedule III thereto and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed as '**ANNEXURE B**'.

3. Appointed Practicing Company Secretary, CS Akshat Garg, Proprietor of M/s Akshat Garg & Associates (Membership No. F9161; CP No. 10655), as Scrutinizer, who has consented to act as such, for conducting the remote e-voting process as well as the e-voting system on the date of the Extra Ordinary General Meeting, in a fair and transparent manner.

4. Chandan Healthcare Limited has entered into an exclusive partnership with Jeena Sikho Lifecare Limited to establish diagnostic centres in all existing and upcoming Jeena Sikho hospitals and clinics across India. Under this agreement, Chandan Healthcare will serve as the exclusive diagnostic partner of Jeena Sikho Lifecare Limited.

5. Discussed all matters contained in the Notice of Extra Ordinary General Meeting in detail and approved draft of Extra Ordinary General Meeting Notice and authorised Executive Directors and Company Secretary to send Extra Ordinary General Meeting Notice to all the Members of the Company under the provisions of the Companies Act, 2013 read with rules made thereunder. The copy of the Extra Ordinary General Meeting Notice will be submitted to the Stock Exchange as soon as the same be emailed to the eligible Shareholders.

Kindly take the same on your record and oblige us.

Yours faithfully,

For Chandan Healthcare Limited

RAJEEV NAIN

Digitally signed by RAJEEV NAIN
Date: 2025.10.10 10:01:18 +05'30'

Rajeev Kumar Nain

Company Secretary & Compliance Officer
Place: Lucknow

ANNEXURE A

Disclosures a required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

AMENDMENTS TO MEMORANDUM OF ASSOCIATION OF THE COMPANY:

The Board of Directors of the Company at its Meeting held today i.e. October 10, 2025, has resolved to amend "clause 5" (Capital Clause) of the Memorandum of Association of the Company subject to approval of the shareholders to be obtained.

The Current Authorized Capital of the Company is Rupees 25,00,00,000.00 (Rupees Twenty Five Crore only) divided into 25000000 (Two Crore Fifty Lakh only) Equity Shares of Rupees 10.00 (Rupees Ten Only) each. The Company proposes to increase its authorized share capital to Rupees 30,00,00,000/- (Rupees Thirty Crores Only) divided into 30000000 (Three Crore) Equity Shares of Rupees 10.00 (Rupees Ten Only) each to facilitate fund raising in future via issuance of equity shares.

The increase in the Authorized Share Capital of the Company will also require consequential amendment in the Clause 5 of the Memorandum of Association of the Company and pursuant to Section 13 and 61 the Companies Act, 2013, alteration of the Capital Clause requires approval of the members. Therefore, the proposed Clause 5 of the Memorandum of Association of the Company after Increase in Authorized Share Capital will be as follows:

"The Authorized Share Capital of the Company is Rupees 30,00,00,000/- (Rupees Thirty Crores Only) divided into 30000000 (Three Crore) Equity Shares of Rupees 10.00 (Rupees Ten Only) each."

ANNEXURE B

Disclosures a required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

DETAILS REGARDING PREFERENTIAL ALLOTMENT OF EQUITY SHARES

S. No.	Particulars	Details
1.	Type of securities proposed to be issued (viz. Equity shares, convertibles etc.);	Fully Convertible Equity Warrants
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.);	Preferential Issue on a private placement basis in accordance with the provisions of the Companies Act, 2013 and the rules made thereunder, Chapter V of the SEBI ICDR Regulations and other applicable laws.
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	Up to 44,50,000 Fully Convertible Equity Warrants ("Warrant(s)") each convertible into or exchangeable for, 1 (one) fully paid-up equity share of the Company of face value of Rupees 10.00 each at an issue price as may be determined in accordance with SEBI (ICDR) Regulations, 2018.
4.	In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):	As under:
4A.	**Names and Number of the investors – EQUITY WARRANTS**	**18 Investors as under;**
		1. NEGEN UNDISCOVERED VALUE FUND
		2. NEGEN CAPITAL SERVICES PRIVATE LIMITED
		3. DIVYA HITESH RAMBHIA
		4. AMAR SINGH
		5. JEENA SIKHO LIFECARE LIMITED
		6. RASHMI SHARMA
		7. NISHITH SADH
		8. DIVYA VARSHNEY
		9. RAJNISH VARSHNEY
		10. COMPACT STRUCTURE FUND
		11. RESHMA PANWAR
		12. ASMITA SINGH
		13. AASTI SINGH
		14. ANANT SINGH
		15. SHAILENDRA SINGH
		16. JAI GOYAL
		17. AMAN WALIA
		18. RAVI KUMAR

<table>
<tr><td rowspan="7">5.</td><td>Post allotment of securities - outcome of the subscription</td><td colspan="4">As under</td></tr>
<tr><td>Number of Investors</td><td colspan="4">Total 3 Investors (Equity Warrants)</td></tr>
<tr><td rowspan="2">Category of Shareholder</td><td colspan="2">Pre-Preferential Issue[1]</td><td colspan="2">Post-Preferential Issue[2]</td></tr>
<tr><td>No. of Shares</td><td>%</td><td>No. of Shares</td><td>%</td></tr>
<tr><td>Promoters & Promoters' Group</td><td>12095684</td><td>49.47</td><td>12495684</td><td>43.23</td></tr>
<tr><td>Public</td><td>12356380</td><td>50.53</td><td>16406380</td><td>56.77</td></tr>
<tr><td>Total</td><td>24452064</td><td>100.00</td><td>28352064</td><td>100.00</td></tr>
<tr><td></td><td colspan="5">Notes:
1. As on October 10, 2025.
2. The post issue shareholding pattern in the above table has been prepared on the basis that the proposed allottee(s) will subscribe to all the equity warrants which they intend to do so and on fully diluted basis and the pre-issue share holding pattern continue to be the same. In the event for any reason, the proposed allottee(s) do not or are unable to subscribe to and/or are not allotted the Equity Shares or warrants, the shareholding pattern in the above table would undergo corresponding changes. Moreover, it is presumed that all the warrants subscribed will be converted into equity shares.</td></tr>
<tr><td>6.</td><td>Issue Price – EQUITY & EQUITY WARRANTS</td><td colspan="4">As may be determined in accordance with SEBI (ICDR) Regulations, 2018</td></tr>
<tr><td>7.</td><td>In case of convertibles: intimation of conversion of securities or on lapse of the tenure of the instrument</td><td colspan="4">Each Equity Warrant will be convertible into, or exchangeable for, 1 (one) fully paid-up equity share of the Company of face value of Rupees 10.00 each payable in cash, which may be exercised in one or more tranches.</td></tr>
<tr><td>8.</td><td>Any cancellation or termination of proposal for issuance of securities including reasons thereof</td><td colspan="4">Nil</td></tr>
</table>